Related Experiment Video
Updated: Aug 12, 2025
12:04
The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
Published on: November 1, 2015
17.8K
Refractory Systemic Lupus Erythematosus: Identification and Pharmacological Management
Dario Roccatello1, Savino Sciascia2, Daniela Rossi2
1University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, Piazza del Donatore di Sangue 3, 10154, Turin, Italy. dario.roccatello@unito.it.
Drugs
|February 2, 2023
Summary
Systemic lupus erythematosus (SLE) is a complex autoimmune disease. This review focuses on real-world evidence for managing severe or refractory SLE, aiming to improve patient outcomes.
Area of Science:
- Immunology
- Rheumatology
- Internal Medicine
Background:
- Systemic lupus erythematosus (SLE) presents heterogeneously, affecting multiple organ systems.
- While steroid introduction reduced SLE mortality, severe/refractory forms persist, causing organ damage and increased morbidity.
- Patients with comorbidities in SLE often face poorer prognoses.
Purpose of the Study:
- To review real-world evidence on clinical features, prognosis, and treatment of severe/refractory SLE.
- To analyze data from a specialized Italian center (CMID, Turin) and existing literature.
- To focus on dermatological, neuropsychiatric, and renal manifestations in severe SLE.
Main Methods:
- Review of clinical research and real-world evidence from the University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (CMID).
- Analysis of existing literature focusing on severe and/or refractory SLE.
- Examination of key clinical, prognostic, and therapeutic features, particularly for dermatological, neuropsychiatric, and renal symptoms.
Main Results:
- Severe/refractory SLE poses significant challenges despite treatment advances.
- Real-world data is crucial due to limited randomized controlled trials in this patient group.
- Understanding prognostic factors and therapeutic strategies is key for improved outcomes.
Conclusions:
- Prompt and appropriate treatment is essential for improving the prognosis of severe/refractory SLE.
- Real-world evidence from specialized centers provides valuable insights into managing complex SLE cases.
- Further research is needed to optimize care for patients with severe SLE, especially those with comorbidities.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
169
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
169
01:26Psychosis: Goals of Pharmacotherapy
183
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
183
01:26Nephrotic Syndrome II : Assessment and Medical Management
14
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
14
01:21Rheumatic Heart Disease III: Medical Management
24
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
24
01:30Heart Failure V: Medical Management
19
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19
01:20Rheumatic Heart Disease IV: Nursing Management
30
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
30